Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques
Abstract
There is an urgent requirement for safe and effective vaccines to prevent novel coronavirus disease (COVID-19) caused by SARS-CoV-2. A concern for the development of new viral vaccines is the potential to induce vaccine-enhanced disease (VED). This was reported in several preclinical studies with both SARS-CoV-1 and MERS vaccines but has not been reported with SARS-CoV-2 vaccines. We have used ferret and rhesus macaques challenged with SARS-CoV-2 to assess the potential for VED in animals vaccinated with formaldehyde-inactivated SARS-CoV-2 (FIV) formulated with Alhydrogel, compared to a negative control vaccine in ferrets or unvaccinated macaques. We showed no evidence of enhanced disease in ferrets or rhesus macaques given FIV except for mild transient enhanced disease seen at seven days post infection in ferrets. This increased lung pathology was observed early in the infection (day 7) but was resolved by day 15. We also demonstrate that formaldehyde treatment of SARS-CoV-2 reduces exposure of the spike receptor binding domain providing a mechanistic explanation for suboptimal immunity.
Competing Interest Statement
Sarah Gilbert and Teresa Lambe are named on a patent application covering a vaccine ChAdOx1 nCoV-19. The remaining authors declare no competing interests.
Subject Area
- Biochemistry (11703)
- Bioengineering (8718)
- Bioinformatics (29127)
- Biophysics (14930)
- Cancer Biology (12048)
- Cell Biology (17353)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18266)
- Genetics (12219)
- Genomics (16765)
- Immunology (11841)
- Microbiology (28003)
- Molecular Biology (11551)
- Neuroscience (60804)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3229)
- Physiology (4939)
- Plant Biology (10383)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)